Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,251.27
(
-1.02%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: joethdo post# 136757

Thursday, 02/09/2012 10:52:55 AM

Thursday, February 09, 2012 10:52:55 AM

Post# of 257580
The new guidance for operating cash burn excluding collaborative revenue from NVS (effectively reimbursement for MNTA’s R&D) and excluding MNTA’s small Lovenox royalty payable to MIT is $22-28M per quarter.

The above guidance includes an unspecified amount for MNTA’s portion of ongoing legal fees for the Lovenox patent case. (NVS pays 100% of the ongoing legal fees in the Copaxone patent case.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today